Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Publication | Closed Access

DOI

255

Citations

References

2015

Year

Jean‐Jacques Grob, Mayur M. Amonkar, Bogusława Karaszewska, Jacob Schachter, Reinhard Dummer, Andrzej Maćkiewicz, Daniil Stroyakovskiy, Kamil Drucis, Florent Grange, Vanna Chiarion‐Sileni,

The Lancet Oncology

MedicineMelanomaClinical TrialsPharmacotherapyDermatologyTrametinib Combination TherapyCancer TreatmentOncologyMolecular OncologyPhase 3Vemurafenib MonotherapySkin Cancer